Electra Therapeutics (NASDAQ:ETRA) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Electra Therapeutics (NASDAQ:ETRA) to a hold rating in a research report released on Saturday morning,Wall Street Zen reports.

Electra Therapeutics Stock Performance

NASDAQ:ETRA opened at $11.32 on Friday. Electra Therapeutics has a one year low of $11.14 and a one year high of $15.50.

Insider Buying and Selling

In related news, Director Orbimed Advisors Llc bought 1,333,333 shares of the company’s stock in a transaction dated Monday, September 21st. The shares were bought at an average price of $15.00 per share, for a total transaction of $19,999,995.00. Following the completion of the acquisition, the director directly owned 5,126,891 shares of the company’s stock, valued at $76,903,365. This trade represents a 35.15% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Carl L. Gordon bought 1,333,333 shares of the company’s stock in a transaction dated Monday, September 21st. The stock was bought at an average price of $15.00 per share, for a total transaction of $19,999,995.00. Following the acquisition, the director directly owned 5,126,891 shares of the company’s stock, valued at approximately $76,903,365. This represents a 35.15% increase in their ownership of the stock. The SEC filing for this purchase provides additional information.

Electra Therapeutics Company Profile

Electra Therapeutics, Inc is a clinical-stage biopharmaceutical company developing therapies for severe immune-mediated diseases. The company is focused on creating treatments designed to selectively remove disease-causing immune cells while preserving healthy immune cells.

Electra’s lead product candidate, ELA026, is an investigational antibody being developed for conditions involving harmful immune-cell activity. The company is evaluating the candidate in clinical studies for diseases including systemic sclerosis and immune thrombocytopenia.

Electra Therapeutics is headquartered in the United States and is focused primarily on advancing its pipeline through clinical development.